Healthcare’s Once-in-a-Generation Disruption
The cost of healthcare in the United States continues to rise and the availability continues to decline. Healthcare spending accounts for 18% of U.S. GDP, and the costs in the U.S. are the highest in the world, increasing 130% in just the last decade. With this complexity comes an opportunity for entrepreneurs, innovators, and investors. iSelect is focused on finding technologies and innovations that reduce costs, increase accessibility, and improve quality of care.
iSelect Portfolio Companies
iSelect focuses on early-stage healthcare companies that are poised to help push the next healthcare revolution forward. We deliberately invest in companies that can make a positive impact on our society, as well as on the bottom line.
Meet Our Selection Committee
Our Healthcare Selection Committee consists of industry and subject matter experts who help guide iSelect’s investment decisions. With firsthand experience and a true pulse on the industry, we consider these individuals key to our success in finding and investing in healthcare innovation.
Ruchir Sehra, M
Jill Davies is
Jin-Moo Lee, MD
Emily Fassi is
Dr. David Messi
Dr. Bruce Germa
Jean Roberson i
A regulatory pr
Andy Daniels is
Dr. Paul D. Oli
Bobby Sandage i
Mr. Don Imholz
Professor of In
Dr. John Talley
Dr. Rutter is f
Mark has served
Dr. Panagos is
Dr. Raghavan br
Edwards was emp
Professor of Me
Join Our Healthcare Innovation Network
Join the thousands of entrepreneurs, investors, and industry professionals driving the future of healthcare.
Resources and News
There’s a lot we still don’t know about the power of genetic testing. For one thing, it’s becoming more powerful than ever expected. Already, patients can get gene-based information about their cancer risk, for instance, as well as details about genetic disorders that might impact their children, autism diagnoses, and more.
It’s been a long time coming, but technology is finally transforming the healthcare industry, enabling functions and services that were all but unimaginable just a few years ago. Case in point: data.
Genetics is changing the world as we know it, and not only in the realm of healthcare and medical science. Whether it’s 23andMe delivering specific details about our ancestry, genetic science being used to united people who have been switched at birth, or even DNA information being used to catch the Golden State Killer, there is much that genomics can now accomplish.
One thing is for sure: we’re not drinking enough water. None of us. And it’s damaging our health. That was the message of a recent article in The New York Times.
Up to three-fourths of Americans are chronically dehydrated, and the condition can be far more debilitating than it might seem. Mild dehydration — literally, not drinking enough water on a day-to-day basis — can impair cognitive performance by up to 20%, affecting reaction time, mental accuracy and memory. More severe cases, however, can result can result in seizures, brain damage, shock, and death.
If a person’s DNA is the roadmap of their lifetime health, their RNA is more of a real-time barometer, recording what happens in their body on a minute-by-minute basis. Our DNA stores and transfers genetic information, but remains little changed throughout our lives. At best, it can tell us about the probability we will someday develop various diseases — whether or not we will get cancer, for instance, or be susceptible to diabetes or heart disease — but it can’t tell us much about our current health.
Flywheel is building an archive of scientific developments, methods and tools so that future researchers will be able to build on those discoveries.
Genetic testing has gone mainstream — consider examples like 23andMe and even Ancestry.com, which both offer genetic analysis by mail — and the market is on track to exceed $10 billion in the next several years.
So people ask me what the optimal, or perfect, iSelect investment opportunity looks like. And there's a scientific, or a finance type of answer that I can give you that we're looking for a company that has an opportunity to have a 10 times return to our investor, or...
On today's podcast, Cofactor Genomics COO, Dr. David Messina discusses how his company is working to make personalized medicine a reality by focusing on the potential of RNA as a diagnostic tool. Unlike DNA, which is set in stone at birth, our RNA changes on a...
Obesity drug developer, Gila Therapeutics, recently took a big step toward FDA approval for its new weight control treatment, completing its Phase I clinical trial in August. Gila is developing a novel intra-oral delivery of PYY, a well-known satiety hormone, to help...
Medicine has always been a science of averages. Most people in the population tend to suffer from most of the same diseases, and most of those diseases respond to most of the same treatments. If one therapy doesn’t work, doctors always have other drugs and other...